SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Status:
RECRUITING
Trial end date:
2027-01-20
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.
Phase:
PHASE3
Details
Lead Sponsor:
Jun Huang
Treatments:
Drug Therapy Fluorouracil Radiosurgery sintilimab spartalizumab